By Jocelyn Anderson Another UC Davis technology could be on its way to the marketplace. Professor Charles Hunt has invented a light source that is environmentally friendly, energy efficient, long lasting and dimmable and delivers pleasant illumination. Perhaps best of all, it’s also low cost. “[Our version of the most commonly used] A19 that replaces […]
The University of California, Davis, and Lawrence Livermore National Laboratory (LLNL) have signed a memorandum of understanding to expand collaborations in research initiatives and educational opportunities. “This agreement builds on a long-standing partnership and leverages the strengths of both institutions,” says UC Davis Associate Vice Chancellor for Research Paul Dodd. The agreement targets four areas […]
By Jocelyn Anderson Plant pathologist Bryce Falk and his research team scored $4.5 million for three years from the U.S. Department of Agriculture’s Specialty Crops Research Initiative to address citrus greening disease — and Falk credits much of the success to the special unit at the Office of Research that helped put together the application. […]
The Science Translation and Innovative Research (STAIR*) Grant program, managed by Venture Catalyst, in close collaboration with InnovationAccess, is designed to provide funding to support translational science and innovative research performed by UC Davis researchers. The inaugural STAIR Grant Program was launched in March 2014. Applications were due on May 2, 2014, and awards were […]
By Jocelyn Anderson Water usage may be California’s No. 1 topic in 2015 — and last year and the one before that. As the state enters its fourth year of drought, everyone is seeking new options for monitoring and usage of this precious resource. In September, Governor Jerry Brown signed groundwater legislation, paving the way […]
From UC Davis Comprehensive Cancer Center Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor’s ability to […]
